Physiology of alpha-fetoprotein as a biomarker for perinatal distress: Relevance to adverse pregnancy outcome

Experimental Biology and Medicine

Volumn 232, Issue 8, 2007, Pages 993-1004

  Mizejewski, Gerald J ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

Alpha fetoprotein; Biomarker; Birth defects; Fetal distress; Pregnancy outcome

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER;

DIAGNOSTIC PROCEDURE; FETUS DISTRESS; HUMAN; PERINATAL DEVELOPMENT; PERINATAL PERIOD; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SHORT SURVEY;

ALPHA-FETOPROTEINS; ANTIBODIES; ANTIBODY SPECIFICITY; BIOLOGICAL MARKERS; BODY FLUIDS; FEMALE; FETAL DISTRESS; HUMANS; IMMUNOASSAY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTERS; PROTEIN ISOFORMS; SENSITIVITY AND SPECIFICITY;

EID: 34548433585     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0612-MR-291     Document Type: Short Survey

References (132)

1. Mizejewski GJ. Alpha-fetoprotein as a biologic response modifier: relevance to domain and subdomain structure. Proc Soc Exp Biol Med 215:333-362, 1997.
2. Abelev GI, Eraiser TL. Cellular aspects of alpha-fetoprotein reexpression in tumors. Semin Cancer Biol 9:95-107, 1999.
3. Luft AJ, Lorscheider FL. Structural analysis of human and bovine alpha-fetoprotein by electron microscopy, image processing, and circular dichroism. Biochemistry 22:5978-5981, 1983.
4. Mizejewski GJ. The phylogeny of alpha-fetoprotein in vertebrates: survey of biochemical and physiological data. Crit Rev Eukaryot Gene Expr 5:281-316, 1995.
5. Long L, Davidson JN, Spear BT. Striking differences between the mouse and the human alpha-fetoprotein enhancers. Genomics 83:694-705, 2004.
6. Mizejewski GJ. Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease states. Obstet Gynecol Surv 58: 804-826, 2003.
7. Dashe JS, Twickler DM, Santos-Ramos R, McIntire DD, Ramus RM. Alpha-fetoprotein detection of neural tube defects and the impact of standard ultrasound. Am J Obstet Gynecol 195:1623-1628, 2006.
8. Rozenberg P, Bussieres L, Chevret S, Bernard JP, Malagrida L, Cuckle H, Chabry C, Durand-Zaleski I, Bidat L, Lacroix I, Moulis M, Roger M, Jacquemot MC, Bault JP, Boukobza P, Boccara P, Vialard F, Giudicelli Y, Ville Y. Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. Am J Obstet Gynecol 195: 1379-1387, 2006.
9. Drugan A, Weissman A, Evans MI. Screening for neural tube defects. Clin Perinatol 28:279-287, vii, 2001.
10. Muller F. Prenatal biochemical screening for neural tube defects. Childs Nerv Syst 19:433-435, 2003.
11. Benn PA, Ying J. Preliminary estimate for the second-trimester maternal serum screening detection rate of the 45,X karyotype using alpha-fetoprotein, unconjugated estriol and human chorionic gonadotropin. J Matern Fetal Neonatal Med 15:160-166, 2004.
12. Duric K, Skrablin S, Lesin J, Kalafatic D, Kuvacic I, Suchanek E. Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy. Eur J Obstet Gynecol Reprod Biol 110: 12-15, 2003.
13. Sharony R, Amiel A, Bouaron N, Kidron D, Itzhaky D, Fejgin M. Congenital deficiency of alpha-fetoprotein and associated chromosomal abnormality in the placenta. Am J Med Genet A 121:113-117, 2003.
14. Bartha JL, Comino-Delgado R, Arce F, Alba P, Broullon JR, Barahona M. Relationship between alpha-fetoprotein and fetal erythropoiesis. J Reprod Med 44:689-697, 1999.
15. Chen H, Egan JO, Chiu JF. Regulation and activities of alpha-fetoprotein. Crit Rev Eukaryot Gene Expr 7:11-41, 1997.
16. Johnson PJ, Poon TC, Hjelm NM, Ho CS, Blake C, Ho SK. Structures of disease-specific serum alpha-fetoprotein isoforms. Br J Cancer 83: 1330-1337, 2000.
17. Moldogazieva NT, Terent'ev AA, Shaitan KV. [Relationship between structure and function of alpha-fetoprotein: conformational status and biological activity]. Biomeditsinskaia khimiia 51:127-151, 2005.
18. Lazarevich NL. Molecular mechanisms of alpha-fetoprotein gene expression. Biochemistry (Mosc) 65:117-133, 2000.
19. Gillespie JR, Uversky VN. Structure and function of alpha-fetoprotein: a biophysical overview. Biochim Biophys Acta 1480: 41-56, 2000.
20. Terentiev AA, Moldogazieva NT. Structural and functional mapping of alpha-fetoprotein. Biochemistry (Mosc) 71:120-132, 2006.
21. Lamerz R. AFP isoforms and their clinical significance (overview). Anticancer Res 17:2927-2930, 1997.
22. Ichikawa E, Kuriyama S, Yuji J, Masaki T, Uchida N, Nishioka M, Taketa K. Further resolution of alpha-fetoprotein glycoforms by two-dimensional isoelectric focusing and lectin affinity electrophoresis. Electrophoresis 27:3480-3487, 2006.
23. Taketa K. Characterization of sugar chain structures of human alpha-fetoprotein by lectin affinity electrophoresis. Electrophoresis 19:2595-2602, 1998.
24. Taketa K. Multimodal application of lectin affinity electrophoresis of alpha-fetoprotein. Electrophoresis 19:1774-1779, 1998.
25. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood) 226:377-408, 2001.
26. Kang Y, Matsuura E, Sakamoto T, Sakai M, Nishi S. Analysis of epitopes of mouse monoclonal antibodies against human alpha-fetoprotein. Tumour Biol 22:254-261, 2001.
27. Yakimenko EF, Yazova AK, Goussev AI, Abelev GI. Epitope mapping of human alpha-fetoprotein. Biochemistry (Mosc) 66:524-530, 2001.
28. Uversky VN, Narizhneva NV, Kirschstein SO, Winter S, Lober G. Conformational transitions provoked by organic solvents in beta-lactoglobulin: can a molten globule like intermediate be induced by the decrease in dielectric constant? Fold Des 2:163-172, 1997.
29. Beneduce L, Castaldi F, Marino M, Tono N, Gatta A, Pontisso P, Fassina G. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers 19:155-159, 2004.
30. Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther 2: 709-735, 2002.
31. Fukasawa H, Iwamoto H, Hirata S, Shoda T, Yokota S, Nishi S, Hoshi K. Novel human alpha-fetoprotein mRNA isoform lacking exon 1 identified in ovarian yolk sac tumor. J Soc Gynecol Investig 12:456-462, 2005.
32. Kubota H, Storms RW, Reid LM. Variant forms of alpha-fetoprotein transcripts expressed in human hematopoietic progenitors. Implications for their developmental potential towards endoderm. J Biol Chem 277:27629-27635, 2002.
33. Yazova AK, Goussev AI, Christiansen M, Kushlinsky NE, Stogova E, Norgaard-Pedersen B, Abelev GI. Human fetal and tumor alpha-fetoproteins differ in conformationally dependent epitope variants expression. Immunol Lett 85:261-270, 2003.
34. Leong SS, Middelberg AP. The refolding of different alpha-fetoprotein variants. Protein Sci 15:2040-2050, 2006.
35. Arsenov DV, Golubeva MB, Kisel MA, Konoplya NA, Lyubin GS, Kuz'mitskii BB, Strel'chenok OA. Modification of humoral immune response in C57Bl/6 mice with a complex of alpha-fetoprotein and retinoid acid derivatives. Bull Exp Biol Med 132:963-965, 2001.
36. Milligan SR, Khan O, Nash M. Competitive binding of xenobiotic oestrogens to rat alpha-fetoprotein and to sex steroid binding proteins in human and rainbow trout (Oncorhynchus mykiss) plasma. Gen Comp Endocrinol 112:89-95, 1998.
37. Mizejewski GJ. An apparent dimerization motif in the third domain of alpha-fetoprotein: molecular mimicry of the steroid/thyroid nuclear receptor superfamily. Bioessays 15:427-432, 1993.
38. Dauphinee MJ, Mizejewski GJ. Human alpha-fetoprotein contains potential heterodimerization motifs capable of interaction with nuclear receptors and transcription/growth factors. Med Hypotheses 58:453-461, 2002.
39. Bois-Joyeux B, Chauvet C, Nacer-Cherif H, Bergeret W, Mazure N, Giguere V, Laudet V, Danan JL. Modulation of the far-upstream enhancer of the rat alpha-fetoprotein gene by members of the ROR alpha, Rev-erb alpha, and Rev-erb beta groups of monomeric orphan nuclear receptors. DNA Cell Biol 19:589-599, 2000.
40. Wang XW, Xu B. Stimulation of tumor-cell growth by alpha-fetoprotein. Int J Cancer 75:596-599, 1998.
41. Li MS, Li PF, Yang FY, He SP, Du GG, Li G. The intracellular mechanism of alpha-fetoprotein promoting the proliferation of NIH 3T3 cells. Cell Res 12:151-156, 2002.
42. Butterstein G, Morrison J, Mizejewski GJ. Effect of alpha-fetoprotein and derived peptides on insulin- and estrogen-induced fetotoxicity. Fetal Diagn Ther 18:360-369, 2003.
43. Oertel M, Menthena A, Chen YQ, Shafritz DA. Properties of cryopreserved fetal liver stem/progenitor cells that exhibit long-term repopulation of the normal rat liver. Stem Cells 24:2244-2251, 2006.
44. Schnater JM, Bruder E, Bertschin S, Woodtli T, de Theije C, Pietsch T, Aronson DC, von Schweinitz D, Lamers WH, Kohler ES. Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice. J Hepatol 45:377-386, 2006.
45. Butterstein GM, Mizejewski GJ. Alpha-fetoprotein inhibits frog metamorphosis: implications for protein motif conservation. Comp Biochem Physiol A Mol Integr Physiol 124:39-45, 1999.
46. Mizejewski GJ. Biological roles of alpha-fetoprotein during pregnancy and perinatal development. Exp Biol Med (Maywood) 229: 439-463, 2004.
47. Gabant P, Forrester L, Nichols J, Van Reeth T, De Mees C, Pajack B, Watt A, Smitz J, Alexandre H, Szpirer C, Szpirer J. Alpha-fetoprotein, the major fetal serum protein, is not essential for embryonic development but is required for female fertility. Proc Natl Acad Sci U S A 99:12865-12870, 2002.
48. Sharony R, Zadik I, Parvari R. Congenital deficiency of alpha fetoprotein. Eur J Hum Genet 12:871-874, 2004.
49. Dudich E, Semenkova L, Dudich I, Denesyuk A, Tatulov E, Korpela T. Alpha-fetoprotein antagonizes X-linked inhibitor of apoptosis protein anticaspase activity and disrupts XIAP-caspase interaction. FEBS J 273:3837-3849, 2006.
50. Uversky VN, Narizhneva NV, Ivanova TV, Tomashevski AY. Rigidity of human alpha-fetoprotein tertiary structure is under ligand control. Biochemistry 36:13638-13645, 1997.
51. Liang OD, Korff T, Eckhardt J, Rifaat J, Baal N, Herr F, Preissner KT, Zygmunt M. Oncodevelopmental alpha-fetoprotein acts as a selective proangiogenic factor on endothelial cell from the fetomaternal unit. J Clin Endocrinol Metab 89:1415-1422, 2004.
52. Takahashi Y, Ohta T, Mai M. Angiogenesis of AFP producing gastric carcinoma: correlation with frequent liver metastasis and its inhibition by anti-AFP antibody. Oncol Rep 11:809-813, 2004.
53. Li MS, Li PF, Chen Q, Du GG, Li G. Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol 10:819-824, 2004.
54. Um SH, Mulhall C, Alisa A, Ives AR, Karani J, Williams R, Bertoletti A, Behboudi S. Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol 173:1772-1778, 2004.
55. Murgita RA, Tomasi TB Jr. Suppression of the immune response by alpha-fetoprotein on the primary and secondary antibody response. J Exp Med 141:269-286, 1975.
56. Mizejewski G, Muehlemann M, Dauphinee MJ. Update of alpha-fetoprotein growth inhibitory peptides as chemotherapeutic agents for tumor growth and metastasis. Chemotherapy 52:83-90, 2006.
57. Mizejewski GJ, Eisele L, Maccoll R. Anticancer versus antigrowth activities of three analogs of the growth-inhibitory peptide: relevance to physicochemical properties. Anticancer Res 26:3071-3076, 2006.
58. Bui LA, Butterfield LH, Kim JY, Ribas A, Seu P, Lau R, Glaspy JA, McBride WH, Economou JS. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther 8:2173-2182, 1997.
59. Vollmer CM, Jr., Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 59:3064-3067, 1999.
60. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS. T cell responses to HLA-A*0201- restricted peptides derived from human alpha fetoprotein. J Immunol 166:5300-5308, 2001.
61. Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 118:1194-1204, 2006.
62. Hanke P, Rabe C, Serwe M, Bohm S, Pagenstecher C, Sauerbruch T, Caselmann WH. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 37:949-955, 2002.
63. Sargent IL, Borzychowski AM, Redman CW. NK cells and human pregnancy-an inflammatory view. Trends Immunol 27:399-404, 2006.
64. Ritter M, Ali MY, Grimm CF, Weth R, Mohr L, Bocher WO, Endrulat K, Wedemeyer H, Blum HE, Geissler M. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. J Hepatol 41:999-1007, 2004.
65. Seralini GE, Stora C. Inhibition of murine genital function by alpha-fetoprotein. Tumour Biol 8:292-293, 1987.
66. Lambert JC, Seralini GE, Stora C, Vallette G, Vranckx R, Nunez EA. Effects of alphafetoprotein on isolated mouse oocytes. Tumour Biol 7: 91-97, 1986.
67. Seralini GE, Lafaurie M, Krebs B, Stora C. Alphafetoprotein and atretic follicles in the ovary of the pregnant rat. Tumour Biol 7:1-8, 1986.
68. Seralini GE, Lafaurie M, Castelli D, Krebs B, Stora C. [Alphafetoprotein and blockade of the sexual cycle]. C R Acad Sci III 298: 397-402, 1984.
69. Castelli D, Aussel C, Lafaurie M, Ayraud N, Stora C. Immunolocalization of alpha-fetoprotein in the ovary and hypophysis of immature female rats. Histochem J 14:879-887, 1982.
70. Aussel C, Castelli D, La Faurie M, Krebs B, Ayraud N, Stora C, Masseyeff R. Role of alpha-fetoprotein (AFP) in the regulation of ovarian activity during hepatocarcinogenesis and post-natal development. Oncodev Biol Med 3:65-71, 1982.
71. Boyd HA, Myrup C, Wohlfahrt J, Westergaard T, Norgaard-Pedersen B, Melbye M. Maternal serum alpha-fetoprotein level during pregnancy and isolated cryptorchidism in male offspring. Am J Epidemiol 164:478-486, 2006.
72. Chung WC, Pak TR, Weiser MJ, Hinds LR, Andersen ME, Handa RJ. Progestin receptor expression in the developing rat brain depends upon activation of estrogen receptor alpha and not estrogen receptor beta. Brain Res 1082:50-60, 2006.
73. Puts DA, Jordan CL, Breedlove SM. Defending the brain from estrogen. Nat Neurosci 9:155-156, 2006.
74. Bakker J, De Mees C, Douhard Q, Balthazart J, Gabant P, Szpirer J, Szpirer C. Alpha-fetoprotein protects the developing female mouse brain from masculinization and defeminization by estrogens. Nat Neurosci 9:220-226, 2006.
75. De Mees C, Laes JF, Bakker J, Smitz J, Hennuy B, Van Vooren P, Gabant P, Szpirer J, Szpirer C. Alpha-fetoprotein controls female fertility and prenatal development of the gonadotropin-releasing hormone pathway through an antiestrogenic action. Mol Cell Biol 26:2012-2018, 2006.
76. Wiwanitkit V. Interaction between alpha-fetoprotein gene and gonadotropin-releasing hormone and effects on brain sexual differentation: molecular function and biological process. Sex Disabil 24: 169-173, 2006.
77. Newby D, Dalgliesh G, Lyall F, Aitken DA. Alphafetoprotein and alphafetoprotein receptor expression in the normal human placenta at term. Placenta 26:190-200, 2005.
78. Brownbill P, Edwards D, Jones C, Mahendran D, Owen D, Sibley C, Johnson R, Swanson P, Nelson DM. Mechanisms of alphafetoprotein transfer in the perfused human placental cotyledon from uncomplicated pregnancy. J Clin Invest 96:2220-2226, 1995.
79. Butler EL, Dashe JS, Ramus RM. Association between maternal serum alpha-fetoprotein and adverse outcomes in pregnancies with placenta previa. Obstet Gynecol 97:35-38, 2001.
80. Koster EL, Dashe JS, McIntire DD, Ramus RM. Association of maternal serum alpha-fetoprotein with persistent placenta previa. J Matern Fetal Neonatal Med 16:3-7, 2004.
81. Duc-Goiran P, Mignot TM, Robert B, Machavoine F, Mondon F, Hagnere AM, Vacher-Lavenu MC, Danan JL, Vaiman D, Benassayag C, Ferre F. Expression and localization of alpha-fetoprotein mRNA and protein in human early villous trophoblasts. Placenta 27:812-821, 2006.
82. Lafuste P, Robert B, Mondon F, Danan JL, Rossi B, Duc-Goiran P, Mignot TM, Nunez EA, Benassayag C, Ferre F. Alpha-fetoprotein gene expression in early and full-term human trophoblast. Placenta 23: 600-612, 2002.
83. Lambot N, Lybaert P, Boom A, Delogne-Desnoeck J, Vanbellinghen AM, Graff G, Lebrun P, Meuris S. Evidence for a clathrin-mediated recycling of albumin in human term placenta. Biol Reprod 75:90-97, 2006.
84. Pelikan DM, Kanhai HH, De Groot-Swings GM, Mesker WE, Tanke HJ, Scherjon SA. Fetomaternal hemorrhage in relation to chorionic villus sampling revisited. Prenat Diagn 26:201-205, 2006.
85. Pham TT, Benirschke K, Masliah E, Stocker JT, Yi ES. Congenital pulmonary airway malformation (congenital cystic adenomatoid malformation) with multiple extrapulmonary anomalies: autopsy report of a fetus at 19 weeks of gestation. Pediatr Dev Pathol 7: 661-666, 2004.
86. Odibo AO, Sehdev HM, Stamilio DM, Macones GA. Evaluating the thresholds of abnormal second trimester multiple marker screening tests associated with intra-uterine growth restriction. Am J Perinatol 23:363-367, 2006.
87. Wald NJ, Morris JK, Ibison J, Wu T, George LM. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. Prenat Diagn 26:559-564, 2006.
88. Zarzour SJ, Gabert HA, Diket AL, St Amant M, Miller JM, Jr. Abnormal maternal serum alpha fetoprotein and pregnancy outcome. J Matern Fed Med 7:304-307, 1998.
89. Smith GC, Shah I, Crossley JA, Aitken DA, Pell JP, Nelson SM, Cameron AD, Connor MJ, Dobbie R. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol 107:161-166, 2006.
90. Benn PA, Craffey A, Horne D, Ramsdell L, Rodis JF. Elevated maternal serum alpha-fetoprotein with low unconjugated estriol and the risk for lethal perinatal outcome. J Matern Fet Med 9:165-169, 2000.
91. Smith GC, Shah I, White IR, Pell JP, Crossley JA, Dobbie R. Maternal and biochemical predictors of spontaneous preterm birth among nulliparous women: a systematic analysis in relation to the degree of prematurity. Int J Epidemiol 35:1169-1177, 2006.
92. Mulch AD, Stallings SP, Salafia CM. Elevated maternal serum alphafetoprotein, umbilical vein varix, and mesenchymal dysplasia: are they related? Prenat Diagn 26:659-661, 2006.
93. Entezami M, Runkel S, Sarioglu N, Hese S, Weitzel HK. Diagnostic dilemma with elevated level of alpha-fetoprotein in an undiagnosed twin pregnancy with a small discordant holoacardius acephalus. Am J Obstet Gynecol 177:466-468, 1997.
94. Crandall BF, Chua C. Risks for fetal abnormalities after very and moderately elevated AF-AFPs. Prenat Diagn 17:837-841, 1997.
95. Lei U, Wohlfahrt J, Christens P, Westergaard T, Lambe M, Norgaard-Pedersen B, Melbye M. Reproductive factors and extreme levels of maternal serum alpha-fetoprotein: a population-based study. Acta Obstet Gynecol Scand 83:1147-1151, 2004.
96. Shenhav S, Gemer O, Volodarsky M, Zohav E, Segal S. Midtrimester triple test levels in women with severe preeclampsia and HELLP syndrome. Acta Obstet Gynecol Scand 82:912-915, 2003.
97. Killam WP, Miller RC, Seeds JW. Extremely high maternal serum alpha-fetoprotein levels at second-trimester screening. Obstet Gynecol 78:257-261, 1991.
98. Nadel AS, Norton ME, Wilkins-Haug L. Cost-effectiveness of strategies used in the evaluation of pregnancies complicated by elevated maternal serum alpha-fetoprotein levels. Obstet Gynecol 89: 660-665, 1997.
99. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 88:816-822, 1996.
100. Chen CK, Chang YL, Jou ST, Tseng YT, Lee YC. Treatment of mediastinal immature teratoma in a child with precocious puberty and Klinefelter's syndrome. Ann Thorac Surg 82:1906-1908, 2006.
101. Spencer K. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 20: 652-656, 2000.
102. Sari N, Yalcin B, Akyuz C, Haliloglu M, Buyukpamukcu M. Infantile hepatic hemangioendothelioma with elevated serum alpha-fetoprotein. Pediatr Hematol Oncol 23:639-647, 2006.
103. Kovacs T, Csecsei K, Szabo M, Veress L, Toth Z, Papp Z. Outcome of mid-trimester pregnancies complicated by oligohydramnios. Quantitative evaluation of the prognostic value of maternal serum alpha-fetoprotein level. J Perinat Med 19(Suppl 1):397-402, 1991.
104. Cuckle H. Biochemical screening for Down syndrome. Eur J Obstet Gynecol Reprod Biol 92:97-101, 2000.
105. Rausch DN, Lambert-Messerlian GM, Canick JA. Participation in maternal serum screening for Down syndrome, neural tube defects, and trisomy 18 following screen-positive results in a previous pregnancy. West J Med 173:180-183, 2000.
106. Kiran TS, Bethel J, Bhal PS. Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome. J Obstet Gynaecol 25:253-256, 2005.
107. Aagaard-Tillery KM, Buchbinder A, Boente MP, Ramin KD. Beckwith-Wiedemann syndrome presenting with an elevated triple screen in the second trimester of pregnancy. Fetal Diagn Ther 22:18-22, 2007.
108. Sritippayawan S, Vachirasrisoontra C. Adverse pregnancy outcomes after a false-positive second trimester serum screen for Down syndrome in Thai pregnant women. J Med Assoc Thai 88:449-454, 2005.
109. Muller F, Dreux S, Sault C, Galland A, Puissant H, Couplet G, Lemay C, Larcher ME, Renom G. Very low alpha-fetoprotein in Down syndrome maternal serum screening. Prenat Diagn 23:584-587, 2003.
110. Cho S, Durfee KK, Keel BA, Parks LH. Perinatal outcomes in a prospective matched pair study of pregnancy and unexplained elevated or low AFP screening. J Perinat Med 25:476-483, 1997.
111. Baschat AA, Harman CR, Farid G, Chodirker BN, Evans JA. Very low second-trimester maternal serum alpha-fetoprotein: association with high birth weight. Obstet Gynecol 99:531-536, 2002.
112. Smith GC, Wood AM, Pell JP, White IR, Crossley JA, Dobbie R. Second-trimester maternal serum levels of alpha-fetoprotein and the subsequent risk of sudden infant death syndrome. N Engl J Med 351: 978-986, 2004.
113. Hershkovitz R, de Swiet M, Kingdom J. Mid-trimester placentation assessment in high-risk pregnancies using maternal serum screening and uterine artery Doppler. Hypertens Pregnancy 24:273-280, 2005.
114. Ay E, Kavak ZN, Elter K, Gokaslan H, Pekin T. Screening for preeclampsia by using maternal serum inhibin A, activin A, human chorionic gonadotropin, unconjugated estriol, and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy. Aust N Z J Obstet Gynaecol 45:283-288, 2005.
115. Bartha JL, Illanes S, Abdel-Fattah SA, Harrison G, Soothill PW. Maternal serum alpha-fetoprotein, fetal middle cerebral artery blood flow velocity and fetal haemoglobin in pregnancies at risk of fetal anaemia. Prenat Diagn 26:101-104, 2006.
116. Cowans NJ, Spencer K. First and second-trimester biochemical markers of chromosomal anomalies and their relationship to maternal haemoglobin levels. Prenat Diagn 25:693-699, 2005.
117. Yigiter AB, Kavak ZN, Bakirci N, Gokaslan H. Effect of smoking on pregnancy-associated plasma protein A, free beta-human chorionic gonadotropin, and nuchal translucency in the first trimester of pregnancy. Adv Ther 23:131-138, 2006.
118. Barkehall-Thomas A, Wilson C, Baker L, ni Bhuinneain M, Wallace EM. Uterine artery Doppler velocimetry for the detection of adverse obstetric outcomes in patients with elevated mid-trimester beta-human chorionic gonadotrophin. Acta Obstet Gynecol Scand 84:743-747, 2005.
119. Pasupathy D, Smith GC. The analysis of factors predicting antepartum stillbirth. Minerva Ginecol 57:397-410, 2005.
120. Chandra S, Scott H, Dodds L, Watts C, Blight C, Van Den Hof M. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol 189:775-781, 2003.
121. Alkazaleh F, Chaddha V, Viero S, Malik A, Anastasiades C, Sroka H, Chitayat D, Toi A, Windrim RC, Kingdom JC. Second-trimester prediction of severe placental complications in women with combined elevations in alpha-fetoprotein and human chorionic gonadotrophin. Am J Obstet Gynecol 194:821-827, 2006.
122. Roig MD, Sabria J, Valls C, Borras M, Miro E, Ponce J, Vicens JM. The use of biochemical markers in prenatal diagnosis of intrauterine growth retardation: insulin-like growth factor I, Leptin, and alphafetoprotein. Eur J Obstet Gynecol Reprod Biol 120:27-32, 2005.
123. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, Lambert-Messerlian GM, Porter TF, Luthy DA, Comstock CH, Saade G, Eddleman K, Merkatz IR, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 106:260-267, 2005.
124. De Jenlis Sicot B, Deruelle P, Kacet N, Vaillant C, Subtil D. Prenatal findings in epidermolysis bullosa with pyloric atresia in a family not known to be at risk. Ultrasound Obstet Gynecol 25:607-609, 2005.
125. Leschot NJ, Treffers PE, Becker-Bloemkolk MJ, van Zanten S, de Groot WP, Verjaal M. Severe congenital skin defects in a newborn. Case report and relevance of several obstetrical parameters. Eur J Obstet Gynecol Reprod Biol 10:381-388, 1980.
126. Norman M, Eriksson CG, Eneroth P. A comparison between the composition of maternal peripheral plasma and plasma collected from the retroplacental compartment at caesarean section. A study on protein and steroid hormones and binding proteins. Arch Gynecol Obstet 244:215-226, 1989.
127. Sarandakou A, Kassanos D, Phocas I, Kontoravdis A, Chryssicopoulos A, Zourlas PA. Amniotic fluid hormone profiles during normal and abnormal pregnancy. Clin Exp Obstet Gynecol 19:180-188, 1992.
128. Gaucherand P, Guibaud S, Rudigoz RC, Wong A. Diagnosis of premature rupture of the membranes by the identification of alphafetoprotein in vaginal secretions. Acta Obstet Gynecol Scand 73:456-459, 1994.
129. Phocas I, Sarandakou A, Kontoravdis A, Chryssicopoulos A, Zourlas PA. Vaginal fluid prolactin: a reliable marker for the diagnosis of prematurely ruptured membranes. Comparison with vaginal fluid alpha-fetoprotein and placental lactogen. Eur J Obstet Gynecol Reprod Biol 31:133-141, 1989.
130. Harrison RF, Biswas S. Maternal plasma, human placental lactogen, alpha-fetoprotein, prolactin and growth hormone in early pregnancy. Int J Gynaecol Obstet 17:471-476, 1980.
131. Bremme K, Eneroth P, Nilsson B. On the use of alpha-fetoprotein and prolactin in prenatal diagnosis of fetal abnormalities in early pregnancies. Int J Gynaecol Obstet 20:293-300, 1982.
132. Rochelson BL. Are vaginal fluid concentrations of prolactin, alphafetoprotein and human placental lactogen useful for diagnosing ruptured membranes? Br J Obstet Gynaecol 92:427, 1985.